Hypothesis

We propose that age‑related decline in NAD+ levels specifically impairs SIRT3‑mediated mitochondrial antioxidant signaling in cholinergic myenteric neurons, leading to excess ROS, neuronal loss, and reduced acetylcholine‑driven α7‑nAChR activation of M2 macrophages. This creates a feed‑forward inflammatory loop that accelerates motility decline, whereas nitrergic neurons retain higher basal NAD+ and SIRT3 activity, rendering them resistant.

Mechanistic Rationale

• Cholinergic myenteric neurons fire at higher frequencies and rely on calcium‑dependent acetylcholine release, which elevates mitochondrial calcium load and ROS production (2).
• NAD+ fuels SIRT3 deacetylase activity, which activates superoxide dismutase 2 (SOD2) and reduces mitochondrial ROS (4).
• Aging lowers colonic NAD+ levels, diminishing SIRT3 protection preferentially in high‑activity cholinergic cells, while nitrergic neurons, which fire less and express higher baseline SOD2, maintain redox balance (3).
• Loss of acetylcholine reduces α7‑nicotinic receptor signaling on macrophages, shifting the M1/M2 balance toward pro‑inflammatory M1 phenotypes that exacerbate neuron loss (2).
• Thus, NAD+ depletion links metabolic stress, selective cholinergic vulnerability, and inflammation in a single mechanistic chain.

Testable Predictions

1. Aged mice will show lower NAD+ and SIRT3 activity in purified cholinergic myenteric neurons compared with nitrergic counterparts.
2. Pharmacological or dietary NAD+ augmentation (e.g., nicotinamide riboside) will restore SIRT3 activity, decrease ROS, and preserve cholinergic neuron numbers in aged colons.
3. Restored cholinergic signaling will increase α7‑nAChR‑mediated M2 macrophage polarization, reducing M1 markers and slowing motility decline as measured by the 3D‑Transit capsule (6).
4. Nitrerergic neuron number and morphology will remain unchanged by NAD+ treatment, confirming selective cholinergic rescue.

Experimental Approach

• Isolate myenteric ganglia from young (3 mo) and aged (24 mo) mice; separate cholinergic (ChAT‑Cre; tdTomato) and nitrergic (nNOS‑GFP) subsets via FACS.
• Quantify NAD+ levels (enzymatic assay), SIRT3 activity (acetyl‑SOD2 Western blot), and mitochondrial ROS (MitoSOX fluorescence).
• Treat aged mice with nicotinamide riboside (400 mg/kg/day) or vehicle for 12 weeks; repeat neuronal counts (ChAT+, nNOS+), macrophage flow cytometry (CD86+ M1, CD206+ M2), and colonic transit using the 3D‑Transit capsule (6).
• Include a SIRT3 inhibitor control to verify pathway specificity.
• Statistical analysis: two‑way ANOVA with age and treatment factors; power analysis to detect 15 % neuronal difference (α=0.05, β=0.2).

Potential Implications

If NAD+ supplementation selectively protects cholinergic myenteric neurons and improves colonic motility, it would reveal a druggable axis connecting metabolic aging, neurodegeneration, and gut immunity. Conversely, failure to rescue cholinergic loss despite NAD+ repletion would refute the hypothesis and redirect focus to alternative drivers such as microglial‑like enteric macrophage intrinsic changes or extracellular matrix stiffening.